For research use only. Not Intended for Therapeutic Use!
|Tags:||Histamine Re |Histamine Re |Histamine Re ||
|We would like to match the lowest price on market if possible.|
|IUPAC Name:||2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acid|
Bilastine(CAS 202189-78-4) is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.It exerts its effect as a selective histamine H1 receptor antagonist, and has a potency similar to cetirizine and is superior to fexofenadine. It was developed in Spain by FAES Farma. Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.